DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Forde PM, Sun Z, Anagnostou V. et al.
PrE0505: A phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM) – A PrECOG LLC study. ASCO Virtual Scientific Program: American Society of Clinical Oncology.
J Clin Oncol 2020;
38: 9003
DOI: 10.1200/JCO.2020.38.15_suppl.9003.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.